Drug Patents Don’t Last as Long as You Think
The Number Everyone Quotes Is Wrong Twenty years. Ask anyone in the pharmaceutical industry how long a drug patent lasts, […]
Drug Patents Don’t Last as Long as You Think Read Post »
Sell Granulation Systems Before the Drug Patent Expires: How Biopharma Equipment Suppliers Can Turn Drug LOE Timelines Into a Predictable Sales Pipeline
There is a predictable moment in generic drug manufacturing when a company’s capital expenditure committee approves a granulation line that
Turn Drug Patent Cliffs Into Contracts: How Formulation Vendors Win Pediatric Business with LOE Intelligence
The business development playbook at most contract development and manufacturing organizations (CDMOs) and formulation vendors follows a predictable arc: attend
Sell the Drug Patent Cliff Before They Fall Off It: How Biopharma Commercial and Market Access Vendors Can Build Class-Specific LOE Intelligence Reports Into a Scalable Revenue Line
There is a moment inside every biopharma brand team, usually around 36 months before patent expiration, when the commercial organization
FDA Orange Book Monitoring: The Subscription Your Biopharma Clients Will Never Cancel
Every quarter, brand-name pharmaceutical manufacturers risk losing billions in revenue because a generic competitor files an Abbreviated New Drug Application
FDA Orange Book Monitoring: The Subscription Your Biopharma Clients Will Never Cancel Read Post »
Sell the Clock: How Market Access Vendors Win Big by Targeting Drug LOE and Patent Litigation Timelines
There is a moment in every branded drug’s commercial life when a payer’s finance team opens a spreadsheet and starts
Know Before the Patent Drops: How Real-Time ANDA Monitoring Closes Biopharma’s Intelligence Gap
Every year, branded pharmaceutical manufacturers watch billions of dollars in revenue evaporate within months of a patent expiry. Generic filers
Own the Cliff: How Biopharma Data Providers Turn Patent Expiry Into Investor Revenue
Patent cliffs kill revenue. Investors know it. What they often lack is a precise, well-sourced, actionable briefing that tells them
Own the Cliff: How Biopharma Data Providers Turn Patent Expiry Into Investor Revenue Read Post »
Sell To Pharma Using Patent Timelines
The global pharmaceutical industry is entering a period of wealth transfer that has no historical equivalent. Between 2025 and 2030,
Sell To Pharma Using Patent Timelines Read Post »
